76 results
8-K
EX-99.1
UBX
Unity Biotechnology Inc
15 Apr 24
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
7:00am
assets
Total current assets
Property and equipment, net
Operating lease right-of-use assets
Long-term restricted cash
Other long-term assets
Total assets … of long-term debt
Total current liabilities
Operating lease liability, net of current portion
Long-term debt, net
Warrant liability
Total liabilities
8-K
EX-99.1
UBX
Unity Biotechnology Inc
13 Nov 23
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results
4:05pm
and equipment, net
Operating lease right-of-use assets
Long-term restricted cash
Other long-term assets
Total assets
Liabilities and Stockholders … ’ Equity
Current liabilities:
Accounts payable
Accrued compensation
Accrued and other current liabilities
Current portion of long-term debt
Total current
8-K
EX-99.1
lkgm9b
8 Aug 23
UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results
4:04pm
8-K
EX-99.1
n133ke14mxosll 2p
9 May 23
UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results
4:10pm
8-K
EX-99.2
3jz63t
24 Apr 23
UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:05am
8-K
EX-99.1
izsl0ft 3ei2xi
24 Apr 23
UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:05am
8-K
EX-99.1
spygik83 0rkunt
8 Nov 22
UNITY Biotechnology, Inc. Reports Third Quarter 2022
4:09pm
8-K
EX-99.1
a0k4bxjrjffqn
1 Nov 22
UNITY Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:00am
8-K
EX-99.2
w5ne3ox2
1 Nov 22
UNITY Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:00am
424B5
8emchr elpt5c31ed2r
19 Aug 22
Prospectus supplement for primary offering
8:42am